参考文献:1. Keystone EC, Ware CF. Tumor necrosis factor and anti-tumor necrosis factor therapies. J Rheumatol Suppl. 2010;85:27鈥?9. ss="external" href="http://dx.doi.org/10.3899/jrheum.091463">CrossRef 2. Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol. 2011;25(4):549鈥?7. ss="external" href="http://dx.doi.org/10.1016/j.berh.2011.10.004">CrossRef 3. Walsh G. Biopharmaceutical benchmarks 2010. Nat Biotechnol. 2010;28(9):917鈥?4. ss="external" href="http://dx.doi.org/10.1038/nbt0910-917">CrossRef 4. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, / et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151(3):1548鈥?1. 5. Pennica D, Lam VT, Weber RF, Kohr WJ, Basa LJ, Spellman MW, / et al. Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. Biochemistry. 1993;32(12):3131鈥?. ss="external" href="http://dx.doi.org/10.1021/bi00063a027">CrossRef 6. Tesar DB, Bjorkman PJ. An intracellular traffic jam: Fc receptor-mediated transport of immunoglobulin G. Curr Opin Struct Biol. 2010;20(2):226鈥?3. ss="external" href="http://dx.doi.org/10.1016/j.sbi.2010.01.010">CrossRef 7. Punt PJ, van Biezen N, Conesa A, Albers A, Mangnus J, van den Hondel C. Filamentous fungi as cell factories for heterologous protein production. Trends Biotechnol. 2002;20(5):200鈥?. ss="external" href="http://dx.doi.org/10.1016/S0167-7799(02)01933-9">CrossRef 8. Choi BK, Bobrowicz P, Davidson RC, Hamilton SR, Kung DH, Li H, / et al. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast / Pichia pastoris. Proc Natl Acad Sci U S A. 2003;100(9):5022鈥?. ss="external" href="http://dx.doi.org/10.1073/pnas.0931263100">CrossRef 9. Hamilton SR, Bobrowicz P, Bobrowicz B, Davidson RC, Li H, Mitchell T, / et al. Production of complex human glycoproteins in yeast. Science. 2003;301(5637):1244鈥?. ss="external" href="http://dx.doi.org/10.1126/science.1088166">CrossRef 10. Bobrowicz P, Davidson RC, Li H, Potgieter TI, Nett JH, Hamilton SR, / et al. Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast / Pichia pastoris: production of complex humanized glycoproteins with terminal galactose. Glycobiology. 2004;14(9):757鈥?6. ss="external" href="http://dx.doi.org/10.1093/glycob/cwh104">CrossRef 11. Hamilton SR, Davidson RC, Sethuraman N, Nett JH, Jiang Y, Rios S, / et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science. 2006;313(5792):1441鈥?. ss="external" href="http://dx.doi.org/10.1126/science.1130256">CrossRef 12. Hopkins D, Gomathinayagam S, Rittenhour AM, Du M, Hoyt E, Karaveg K, / et al. Elimination of beta-mannose glycan structures in / Pichia pastoris. Glycobiology. 2011;21(12):1616鈥?6. ss="external" href="http://dx.doi.org/10.1093/glycob/cwr108">CrossRef 13. Lowy PH, Keighley G, Borsook H. Inactivation of erythropoietin by neuraminidase and by mild substitution reactions. Nature. 1960;185:102鈥?. ss="external" href="http://dx.doi.org/10.1038/185102a0">CrossRef 14. Lukowsky WA, Painter RH. Studies on the role of sialic acid in the physical and biological properties of erythropoietin. Can J Biochem. 1972;50(8):909鈥?7. ss="external" href="http://dx.doi.org/10.1139/o72-127">CrossRef 15. Goldwasser E, Kung CK, Eliason J. On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem. 1974;249(13):4202鈥?. 16. Stadheim TA, Li H, Kett W, Burnina IN, Gerngross TU. Use of high-performance anion exchange chromatography with pulsed amperometric detection for O-glycan determination in yeast. Nat Protoc. 2008;3(6):1026鈥?1. ss="external" href="http://dx.doi.org/10.1038/nprot.2008.76">CrossRef 17. Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, / et al. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos. 2011;39(9):1469鈥?7. ss="external" href="http://dx.doi.org/10.1124/dmd.111.039453">CrossRef 18. Liu L, Stadheim A, Hamuro L, Pittman T, Wang W, Zha D, / et al. Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized / Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials. Biologicals. 2011;39(4):205鈥?0. ss="external" href="http://dx.doi.org/10.1016/j.biologicals.2011.06.002">CrossRef 19. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, / et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010;184(4):1968鈥?6. ss="external" href="http://dx.doi.org/10.4049/jimmunol.0903296">CrossRef 20. Beck A, Reichert JM. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs. 2011;3(5):415鈥?. ss="external" href="http://dx.doi.org/10.4161/mabs.3.5.17334">CrossRef 21. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22(6):868鈥?6. ss="external" href="http://dx.doi.org/10.1016/j.copbio.2011.06.012">CrossRef 22. Wang YM, Sloey B, Wong T, Khandelwal P, Melara R, Sun YN. Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism. Pharm Res. 2011;28(8):1931鈥?. ss="external" href="http://dx.doi.org/10.1007/s11095-011-0420-y">CrossRef 23. Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu J, Witcher DR, / et al. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved / in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab Dispos. 2012;40(8):1545鈥?5. ss="external" href="http://dx.doi.org/10.1124/dmd.112.045864">CrossRef 24. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos. 2007;35(1):86鈥?4. ss="external" href="http://dx.doi.org/10.1124/dmd.106.011734">CrossRef 25. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001;13(12):1551鈥?. ss="external" href="http://dx.doi.org/10.1093/intimm/13.12.1551">CrossRef 26. Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem. 2010;285(7):4826鈥?6. ss="external" href="http://dx.doi.org/10.1074/jbc.M109.081828">CrossRef 27. Vaughn DE, Bjorkman PJ. High-affinity binding of the neonatal Fc receptor to its IgG ligand requires receptor immobilization. Biochemistry. 1997;36(31):9374鈥?0. ss="external" href="http://dx.doi.org/10.1021/bi970841r">CrossRef 28. Schwartz AL. Trafficking of asialoglycoproteins and the asialoglycoprotein receptor. Target Diagn Ther. 1991;4:3鈥?9. 29. Stahl PD, Ezekowitz RA. The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol. 1998;10(1):50鈥?. ss="external" href="http://dx.doi.org/10.1016/S0952-7915(98)80031-9">CrossRef 30. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 2001;16 Suppl 3:3鈥?3. ss="external" href="http://dx.doi.org/10.1093/ndt/16.suppl_3.3">CrossRef 31. Meier W, Gill A, Rogge M, Dabora R, Majeau GR, Oleson FB, / et al. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol. 1995;2(3):159鈥?1. 32. Stefanich EG, Ren S, Danilenko DM, Lim A, Song A, Iyer S, / et al. Evidence for an asialoglycoprotein receptor on nonparenchymal cells for O-linked glycoproteins. J Pharmacol Exp Ther. 2008;327(2):308鈥?5. ss="external" href="http://dx.doi.org/10.1124/jpet.108.142232">CrossRef
作者单位:Liming Liu (1) Sujatha Gomathinayagam (2) Lora Hamuro (1) Thomayant Prueksaritanont (1) Weirong Wang (1) Terrance A. Stadheim (2) Stephen R. Hamilton (2)
1. Department of Pharmacokinetics, Pharmacodynamics & Drug Metabolism Merck Research Laboratories, West Point, Pennsylvania, 19486, USA 2. Biologics Discovery (GlycoFi, Merck), Merck Research Laboratories, 21 Lafayette Street (Suite 200), Lebanon, New Hampshire, 03766, USA